Recent Advances in the Treatment of Multiple Myeloma: Highlights from the ASH 2021 Meeting : Episode 10
Unmet Needs and Future Perspectives in Multiple Myeloma Treatment
A look at the unmet needs and future directions of multiple myeloma treatment.
EP: 1.Triplet and Quadruplet Induction Regimens for Transplant-Eligible NDMM: Focus on GRIFFIN and MASTER Trials
EP: 2.Choosing Between Triplet and Quadruplet Induction Regimens for Transplant-Eligible NDMM
EP: 3.Treatment Duration and Response to Induction Therapy in Transplant-Eligible NDMM
EP: 4.First-Line Treatment Options for Transplant-Ineligible NDMM: Focus on MAIA Trial
EP: 5.Outcomes with Daratumumab in Frontline Versus Subsequent Lines of Therapy in Transplant-Ineligible MM
EP: 6.Novel BCMA-Targeting Agents for the Treatment of Relapsed/Refractory Multiple Myeloma
EP: 7.BCMA-Targeting Bispecific Agents for Relapsed/Refractory Multiple Myeloma Treatment
EP: 8.CAR-T Therapies in Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 and KarMMA Studies
EP: 9.Novel Agents Under Investigation for Multiple Myeloma
Now Viewing
EP: 10.Unmet Needs and Future Perspectives in Multiple Myeloma Treatment
EP: 11.Recap: A Review of Multiple Myeloma Trials That Impact the Standard of Care
Recent Videos
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
Related Content
